The content on this site is intended for healthcare professionals only
Prof Joseph Gligorov speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about where chemotherapy should be placed in patients with luminal breast cancer and an intermediate risk recurrence score.
He provides further details of this patient population and refers to the results from the TAILORx study, where adjuvant chemotherapy had no effect in this patient group.
Prof Gligorov also mentions that patients who are aged less or equal to 50 years with a risk recurrence score between 16 and 25 may benefit from chemotherapy.
He concludes by stating that patients above the age of 50 should not be given chemotherapy, but younger patients should.
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Short-course radiation as effective as standard treatment for breast cancer patients choosing reconstruction after mastectomy
The Southeast Asian Breast Cancer Symposium; background, aims and successes
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
Assessment of QoL results and correlation with survival outcomes in phase III clinical trials in metastatic NSCLC
Neo-adjuvant therapy for different cancers in the Philippines
